DSM-Firmenich’s surprise move: Apollo gets a second shot as CVC falters in nutrition deal

In a sharp reversal that underscores the fragility of complex carve-outs, DSM-Firmenich (Euronext: DSFIR) has reportedly asked Apollo Global Management to rejoin the auction for its Animal Nutrition & Health (ANH) division after CVC Capital Partners’ bid stalled on structural issues. The development highlights how major divestments are no longer judged solely on headline valuations but on the strength of financing structures, liability frameworks, and execution certainty. With this decision, DSM-Firmenich has reintroduced competitive tension into one of the most closely watched European private equity deals of 2025.

Why did DSM-Firmenich decide to spin off its animal nutrition and health division in the first place?

The decision to separate the ANH business traces back to the strategic repositioning that followed the 2023 merger of Royal DSM and Firmenich. The combined group entered the market as a powerhouse spanning nutrition, fragrances, specialty ingredients, and health solutions. Yet the integration also exposed a structural weakness: its reliance on the cyclical and volatile vitamins segment, where oversupply and pricing pressure have eroded margins for years.

By February 2024, DSM-Firmenich had announced that ANH would be carved out to reduce earnings volatility, sharpen capital allocation, and focus on higher-margin businesses such as fragrance, flavor, and human nutrition. At the time, the ANH unit employed around 6,000 people and delivered revenues exceeding €3 billion. Its portfolio included premixes, feed additives, and precision nutrition services. Importantly, it showed resilience, posting 5 percent organic growth and improving adjusted EBITDA in 2024, even as the broader vitamins market faced persistent headwinds.

The separation is also part of a wider industry trend. Globally, companies in food, agri-tech, and life sciences have been pruning volatile, low-margin divisions while doubling down on specialty ingredients. Investors increasingly reward businesses that focus on differentiated, high-value segments rather than commodity-linked cycles. DSM-Firmenich’s decision is therefore consistent with both shareholder expectations and broader sectoral dynamics.

What went wrong with CVC’s bid and why did Apollo return to the table?

CVC Capital Partners appeared at one stage to be the frontrunner in the auction. DSM-Firmenich had shortlisted CVC and Apollo as the key financial bidders, while Nutreco, a Dutch feed specialist, was considered the leading strategic contender. By mid-2025, however, Nutreco withdrew from the process, leaving CVC as the sole serious bidder. This placed immense pressure on DSM-Firmenich to conclude a deal with CVC.

Reports now suggest that CVC’s bid ran into difficulties not because of valuation, but because of the deal structure itself. Financing conditions, debt sizing, carve-out liabilities, and earn-out mechanics appear to have created misalignment between buyer, seller, and lenders. With up to €2 billion in debt financing being arranged by investment banks to back the transaction, small differences in covenant design or liability allocation can quickly derail a deal.

Faced with the risk of being left with only one structurally weak offer, DSM-Firmenich re-engaged Apollo Global Management. The move reintroduces competitive tension into the auction, strengthens DSM-Firmenich’s negotiating leverage, and signals to CVC that its bid is not the only path forward. For Apollo, the invitation offers a second chance to secure a major European platform in animal nutrition, though it is likely to negotiate more favorable terms to compensate for its late reentry.

How is debt financing shaping the outcome of the DSM-Firmenich auction?

The financing element of this deal is critical. Reports indicate that banks are preparing €2.0 to €2.3 billion in debt capacity to support any acquisition of ANH. The business generates an estimated EBITDA of around €460 million, which places the debt multiple near five times earnings. While such leverage levels are common in private equity, they can quickly become risky in a cyclical market like vitamins and feed additives.

Investors will recall that during past downcycles in the vitamin sector, profitability shrank sharply, leaving balance sheets vulnerable. To prevent a repeat, lenders are expected to demand strict covenants, higher coverage ratios, and greater scrutiny of contingent liabilities. This focus on downside protection explains why CVC’s bid may have faltered. For Apollo, success may depend not only on offering a competitive price but also on demonstrating the ability to build a robust, lender-backed capital structure.

The attention to debt structure also reflects the broader credit environment. With interest rates remaining elevated in Europe and volatility in capital markets persisting, lenders are less willing to underwrite aggressive packages without clear protections. The DSM-Firmenich auction therefore illustrates how financing complexity, not just valuation, now determines outcomes in mega carve-outs.

Who else has been involved in the bidding and why does it matter?

The sale process initially attracted wide interest from both private equity and strategic buyers. Alongside Apollo and CVC, firms such as Bain Capital and Lone Star evaluated the division. On the strategic side, industry leaders like ADM and Cargill monitored the process, but Nutreco was the most active. A Nutreco acquisition would have represented significant consolidation in animal feed and nutrition, potentially delivering synergies in distribution, sourcing, and R&D.

However, Nutreco eventually walked away, reportedly due to valuation concerns and regulatory complexity. Its withdrawal narrowed the contest to financial bidders only, and by July 2025, CVC looked to have a clear path. That changed when its offer stalled, leaving DSM-Firmenich with little choice but to re-engage Apollo. The episode highlights the precariousness of competitive auctions: a process can swing from crowded to fragile in a matter of months, forcing sellers to recalibrate strategy mid-stream.

How has DSM-Firmenich stock responded to the uncertainty?

As a publicly listed company, DSM-Firmenich’s strategy is under constant investor scrutiny. The stock (Euronext: DSFIR) has traded under pressure since the carve-out was announced, reflecting uncertainty about both execution risk and the volatile performance of the vitamins market. Analysts have emphasized that a successful divestment could be a strong catalyst, freeing up capital for share buybacks or reinvestment into the company’s higher-margin businesses.

With the latest news of Apollo’s return, investors may interpret the move as prudent risk management. Instead of being locked into a single struggling bid, DSM-Firmenich has regained leverage. Yet there is also concern that prolonged delays could weigh on valuation. Institutional sentiment appears divided: short-term traders may see volatility, while long-term holders could view the process as a necessary step toward strategic clarity.

In terms of flows, European equity funds have been cautious on DSM-Firmenich due to sectoral weakness in nutrition and vitamins. If a clean, high-multiple deal is announced, buy-side sentiment could shift, potentially supporting a buy recommendation. On the other hand, if the auction drags into 2026 without resolution, analysts may downgrade the stock to hold until visibility improves.

What does this auction reveal about broader M&A trends in nutrition and specialty ingredients?

Beyond the headlines, the DSM-Firmenich ANH auction reflects deeper shifts in global M&A. Companies across food, agriculture, and specialty chemicals are moving away from volatile commodity businesses and concentrating capital on high-margin, stable growth areas. This creates opportunities for private equity firms to step in, carve out divisions, and reposition them for standalone success.

At the same time, the financing environment has become more complex. Elevated interest rates and greater regulatory scrutiny mean that deals increasingly hinge on structural details rather than just price. DSM-Firmenich’s experience illustrates how even large, sophisticated sellers must maintain optionality, diversify bidder pools, and balance financial buyers against strategic interest.

For private equity, the deal underscores the growing role of platform plays in animal nutrition, precision agriculture, and specialty feed. Apollo, with its track record in carve-outs, and CVC, with its capital depth, both see ANH as a potential growth platform. For strategics like Nutreco, the missed opportunity highlights the challenges of competing with financial buyers in an environment where carve-outs are highly leveraged.

DSM-Firmenich’s decision to bring Apollo back into the fold is less about reversing course and more about ensuring resilience. In today’s M&A environment, a single failed bid can stall or even derail a process. By reopening the auction, DSM-Firmenich has shown that it is unwilling to compromise on structure and execution certainty, even if it means prolonging negotiations. Investors and analysts will now watch closely to see whether CVC can resolve its financing impasse, whether Apollo delivers a revised competitive bid, and whether the company ultimately secures a deal that positions ANH for growth while strengthening shareholder value.